Tam-Peli Trial Shows Improved Survival in Relapsed Small-Cell Lung Cancer

The phase III TAISHAN-302 clinical trial has reported that tambotatug pelitecan (Tam-Peli) led to a significant improvement in survival for patients diagnosed with relapsed small-cell lung cancer.

Data from the trial indicated that Tam-Peli reduced the risk of death by 54% when compared to the standard treatment, topotecan. The study also showed improvements in progression-free survival and response rates.

The TAISHAN-302 trial enrolled 323 patients across multiple cancer centers. The primary endpoint for the study was overall survival, with progression-free survival and objective response rate as key secondary endpoints.

Tambotatug pelitecan is an antibody-drug conjugate targeting the B7-H3 protein. B7-H3 is known to be expressed in a variety of cancers, including small-cell lung cancer.